Intro to COVID-19: Combating Fraudulent Products
This session will discuss the varying authorities FDA has to combat fraudulent products including warning letters, seizures, injunctions, and criminal prosecutions.
Cathy L. Burgess, Partner, Alston & Bird LLP, Member, FDLI Board of Directors
This session was recorded as part of FDLI’s virtual course, “COVID-19: Introduction to FDA’s Existing Legal Authorities and Emerging Issues”on August 18, 2020.
Get Access
- +$100 for nonmembers
Virtual Learning FAQ
On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.
On-demand content can be played back on most devices.
CLE credit is not currently available for pre-recorded sessions.
Related Content